All In Biotech

Drug Trial Radar · NCT06454240

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

79

Actual

Start

Jul 17, 2024

Primary completion

Jan 29, 2026

Study completion Apr 23, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups. The study duration will be up to approximately 40 weeks per participant, including 4 weeks of screening run-in period, 24 weeks of intervention period, and 12 weeks of follow-up.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • lunsekimigDrug

    Pharmaceutical form:solution for injection-Route of administration:subcutaneous

  • placeboDrug

    Pharmaceutical form:solution for injection-Route of administration:subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in bilateral endoscopic nasal polyp score (NPS).Time frame: From baseline to Week 24

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Allergy & Rheumatology- Site Number : 8400005

    La Jolla, California

  • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003

    Roseville, California

  • Senta Clinic- Site Number : 8400025

    San Diego, California

  • James A Haley Veterans' Hospital- Site Number : 8400015

    Tampa, Florida

  • Emory University Hospital Midtown- Site Number : 8400012

    Atlanta, Georgia

  • The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002

    Boise, Idaho

  • Harvard Medical School - Brigham and Women's Hospital Site Number : 8400016

    Boston, Massachusetts

  • Essential Medical Research- Site Number : 8400020

    Tulsa, Oklahoma

  • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017

    Bellaire, Texas

  • Gary Gross Pharmaceutical Research & Consulting, Inc. Site Number : 8400004

    Dallas, Texas

  • Berkson Medical - McKinney- Site Number : 8400014

    McKinney, Texas

  • Alamo ENT Associates Site Number : 8400001

    San Antonio, Texas

  • Advanced Research Institute - Odgen- Site Number : 8400022

    Ogden, Utah

  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008

    Norfolk, Virginia

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Mendoza, Argentina

  • Investigational Site Number : 0320002

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0560002

    Ghent, Belgium

  • Investigational Site Number : 0560001

    Leuven, Belgium

  • Investigational Site Number : 1000001

    Sofia, Bulgaria

  • Investigational Site Number : 6160004

    Poznan, Poland

  • Investigational Site Number : 6160007

    Wroclaw, Poland

  • Investigational Site Number : 6160002

    Krakow, Lesser Poland Voivodeship, Poland

  • Investigational Site Number : 6160001

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160005

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160003

    Katowice, Silesian Voivodeship, Poland

  • Investigational Site Number : 8260003

    Manchester, United Kingdom

  • Investigational Site Number : 8260001

    Newcastle upon Tyne, United Kingdom

  • Investigational Site Number : 8260004

    Gloucester, Gloucestershire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.